Olga García

Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

Alfredo Rivas‐Delgado, Laura Magnano, Miriam Moreno‐Velázquez et al. · British Journal of Haematology · 2018 · 83 citations · Full text

Medicine, Immunology, Oncology +13

Validation of the <scp>NCCN</scp>‐<scp>IPI</scp> for diffuse large B‐cell lymphoma (<scp>DLBCL</scp>): the addition of β₂‐microglobulin yields a more accurate <scp>GELTAMO</scp>‐<scp>IPI</scp>

Carlos Montalbán, Antonio Díaz‐López, Iván Dlouhy et al. · British Journal of Haematology · 2017 · 82 citations · Full text

Medicine, Oncology, Cancer Immunology +13

Dose‐intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status

Josep‐María Ribera, Olga García, Carlos Grande et al. · Cancer · 2013 · 69 citations · Full text

Medicine, Hematology, Oncology +14

New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO)

Leyre Bento, Antonio Díaz‐López, Gilberto Barranco-Lampón et al. · British Journal of Haematology · 2019 · 67 citations · Full text

Medicine, Hematology, Oncology +14

Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non‐Hodgkin’s lymphoma patients at high risk of central nervous system disease in the rituximab era

Juan‐Manuel Sancho, Alberto Órfão, Sandra Quijano et al. · European Journal Of Haematology · 2010 · 57 citations

Medicine, Oncology, Pathology +13